Tag

Drug Pricing

All articles tagged with #drug pricing

healthcare7 days ago•3 min saved

TrumpRx.gov Expansion Opens Transparent, Discounted Generics for Americans

President Trump announced an expansion of TrumpRx.gov to list more than 600 generic medications with transparent cash prices, enabling patients to compare the best cash prices at local pharmacies or delivery options against insurance co-pays, and integrating discounts from Amazon Pharmacy, Cost Plus Drugs, and GoodRx; the platform excludes controlled substances and meds not commonly offered direct-to-consumer, building on prior executive actions to lower US drug costs.

via The White House (.gov)|

#drug-pricing #generic-meds #healthcare

politics1 month ago•4 min saved

Trump unveils Regeneron pact to lower Medicaid drug costs

President Trump announced a deal with Regeneron to reduce prices on all Regeneron drugs sold on Medicaid, including Praluent at $225 on the TrumpRx site, as part of a broader White House drug-pricing push. Regeneron also pledged about $27 billion in U.S. R&D/manufacturing investments. Details of the contracts remain largely undisclosed, but the administration is promoting the agreements ahead of the midterm elections as part of its effort to reshape U.S. drug pricing.

via PBS|

#drug-pricing #medicaid #politics

business1 month ago•2 min saved

Regeneron trims prices for some Americans and pledges free hearing-loss gene therapy after FDA nod

Regeneron said it will lower U.S. drug prices for some Americans under President Trump’s pricing plan and will offer its first hearing-loss gene therapy for free to eligible patients after regulatory approval, while also securing a three-year tariff exemption; the therapy Otarmeni targets a rare hearing-loss condition and could reduce reliance on cochlear implants, with analysts signaling potential peak sales around $130 million.

via CNBC|

#business #drug-pricing #gene-therapy

politics1 month ago•38 min saved

Capitol Hill in Overdrive: Fed Oversight, Redistricting, and Immigration Dominate the Week

Capitol Hill is in overdrive as lawmakers tackle a torrent of issues: Senate Republicans push for increased Federal Reserve oversight to help clear the stalled Warsh nomination, while a GOP-leaning standoff over a DOJ probe adds friction. Across the Hill, Rep. Kean Jr.’s health-related absence raises concerns in New Jersey, a marathon “vote-a-rama” on immigration-enforcement funding looms in the Senate, and debate over Iran war powers intensifies as a 60-day clock nears. The Senate also moves to expand AI tools for staff, questions Kennedy’s vaccine policy, and Sanders pushes a drug-pricing amendment. In the House, FISA extension talks continue as the Endangered Species Act bill is pulled, and Virginia Democrats celebrate a redistricting win that has Hakeem Jeffries declaring “maximum warfare” in response. Polls show historic disapproval of Congress amid these fights, alongside ongoing discussions about data privacy and other Republican pregnancies on the Hill.

via Politico|

#congressional-oversight #drug-pricing #federal-reserve

politics1 month ago•31 min saved

House GOP weighs narrow immigration bill against broader reform amid FISA and redistricting drama

Live Capitol Hill updates show House Republicans weighing a quick, party-line reconciliation bill funding immigration enforcement, with support hinging on prospects for a broader package later in the year; leadership struggles over extending 702 FISA and potential long-term protections; the Endangered Species Act bill is pulled amid GOP opposition; discussions about a possible DOJ pardon for Ghislaine Maxwell surface in the Epstein case; Sanders moves to codify Trump's drug-price deals in the budget vote-a-rama; Virginia's mid-decade redistricting sparks intra-party tension as Democrats celebrate map changes; and Congress grapples with historically low public approval while Democrats prepare a marathon of affordability-focused amendments.

via Politico|

#drug-pricing #fisa #maxwell-pardon

politics1 month ago•3 min saved

Kennedy’s Capitol Hill comeback faces diminished clout amid vaccine-policy scrutiny

Health Secretary Robert F. Kennedy Jr. returns to Capitol Hill with diminished autonomy, facing a gauntlet of vaccine-related questions from House Ways and Means, Appropriations, and Senate committees as his administration’s changes—and court setbacks—have undercut his influence; critics cite the January overhaul of the childhood vaccine schedule and CDC updates tied to his stance, while supporters point to drug-pricing deals and new dietary guidelines as he maneuvers a shifting political landscape ahead of the midterms.

via Axios|

#congress #drug-pricing #politics

business1 month ago•39 min saved

Keytruda's fortress: Merck's patent-and-pricing empire under global scrutiny

An ICIJ investigation shows Merck’s Keytruda has become one of the world’s best-selling drugs not just because of therapeutic value but due to an expansive patent portfolio (more than 1,200 filings in 53 countries), lobbying, and pricing tactics that raise costs for patients worldwide while governments and insurers struggle to fund access; the report details price disparities, secrecy, accelerated approvals, and strategic moves like drug-dosing and product hopping that help Merck extend monopoly into the 2030s, with patients in India, Guatemala, the U.S. and elsewhere paying vast out-of-pocket or facing restricted access.

via International Consortium of Investigative Journalists - ICIJ|

#access-to-medicine #business #drug-pricing

politics1 month ago•8 min saved

PhRMA's Steve Ubl to step down by year-end, triggering CEO search

Steve Ubl, CEO of the Pharmaceutical Research and Manufacturers of America, will depart at the end of the year after a decade leading the branded-drug lobby, leaving a leadership gap as Congress pressures lower drug costs and the administration pursues pricing reforms. The board will search for a successor, with Ubl remaining through a smooth transition; Lori Reilly is considered a leading internal candidate as PhRMA navigates IRA-era price negotiations and rising industry scrutiny.

via Politico|

#drug-pricing #lobbying #lori-reilly

health1 month ago•19 min saved

PhRMA chief resigns amid Trump drug-pricing clash

Steve Ubl, PhRMA’s CEO, will step down after steering the drug industry toward a tougher lobbying stance as Washington and President Trump spar over drug prices, including threats of tariffs; a successor will be named as the pricing fight continues.

via The Washington Post|

#donald-trump #drug-pricing #health

health2 months ago•5 min saved

TrumpRx: Small Discounts, Big Questions on Real Price Relief

TrumpRx.gov, launched to curb prescription costs, has offered discounts on only 54 drugs—many with cheaper generics or other savings options—and remains far from an insurance-friendly tool, with limited awareness; experts say its real impact hinges on scale, broader drug coverage, price transparency, and potential congressional action to codify MFN-style deals into law.

via NBC News|

#drug-pricing #health #health-policy

healthcare2 months ago•7 min saved

TrumpRx Promises Grand Savings, Delivers Narrow Drug List After One Month

One month after its launch, TrumpRx has only a small catalog of drugs (44 listed) despite lofty promises of broad discounts, with many items already available as generics and no clear usage data released. Private deals with drugmakers remain in flux, limiting impact on prices, while administration officials trumpet progress amid bipartisan scrutiny and questions about affordability gains for most patients.

via statnews.com|

#drug-pricing #generics #healthcare

health-policy3 months ago•3 min saved

TrumpRx Promises the Cheapest Drugs, Yet Generics Undercut Many Offers

STAT found that TrumpRx markets deep cash discounts for about 43 brand-name drugs, but at least 18 of them have cheaper generics available on GoodRx or Cost Plus Drugs; TrumpRx only displays cash prices and does not sell medicines directly, highlighting that many savings come from generic options rather than the site’s claims.

via statnews.com|

#drug-pricing #generics #health-policy

politics3 months ago•5 min saved

TrumpRx Debuts Amid Skepticism Over Pricing Impact

The White House launched TrumpRx (trumprx.gov) to help uninsured Americans find discounted prices for high-cost, brand-name drugs. It doesn’t sell drugs directly; users browse discounted medicines and either receive coupons at pharmacies or are redirected to manufacturers’ sites. Discounts come from voluntary 'most favored nation' deals with 16 major drugmakers, but full terms are not public. Economists say the savings are likely modest and mainly increase price transparency; the platform could help those not covered by insurance, especially for lifestyle drugs like fertility or weight-loss treatments. Democrats criticize it as a vanity project and raise concerns about potential conflicts with BlinkRx and Trump family involvement; long-term impact remains uncertain.

via latimes.com|

#blinkrx #democrats #drug-pricing

healthcare3 months ago•1 min saved

Most TrumpRx-listed drugs have cheaper generics, study finds

TrumpRx’s price list shows many branded meds have cheaper generic alternatives: for example, Pristiq can be found for about $200 for 30 days, while generics cost under $30 and even as low as $16.65 on CostPlusDrugs. Experts warn the site may not benefit cash buyers and could steer patients toward pricier branded options, though the White House says it aims to offer the lowest-cost branded choices. Regulators note generics are generally safe and equivalent, though some critics point to FDA testing gaps highlighted by investigations.

via Axios|

#costplusdrugs #drug-pricing #generics

politics3 months ago•6 min saved

TrumpRx launches discount drug portal, aims to cut costs but skeptics doubt sweeping savings

President Trump unveiled TrumpRx, a direct-to-consumer site offering discounts on about 40 branded medicines from five major drugmakers with GoodRx backing; experts say savings may be muted for many since insurance plans and deductibles often yield lower costs, and pricing details remain unclear. The administration touts it as transformative, but critics warn it could curb competition and that broader Medicare drug-price negotiations would be more effective. A potential Express Scripts agreement could expand coverage if the regulatory environment allows, signaling that Congress may need to act to count purchases toward deductibles.

via Politico|

#direct-to-consumer #drug-pricing #goodrx